We hereby submit Financial Results for the Half Year and Year ended March 31, 2026.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Speciality Medicines Ltd reported strong full-year FY2026 results with revenue from operations at Rs 7,528.51 Lakh, up 29.2% from Rs 5,827.14 Lakh in FY2025. Net profit surged 81.1% to Rs 1,303.29 Lakh from Rs 719.63 Lakh. EBITDA margin expanded from approximately 16% to 19.1%. The company completed its IPO in March 2026, raising Rs 2,914 Lakh through issuance of 23,50,000 equity shares at Rs 124 each. IPO proceeds utilization stood at Rs 509.15 Lakh as of March 31, 2026. The auditors issued an unmodified opinion, and no investor complaints were pending. The company has only one reportable segment—marketing and distribution of finished pharmaceutical formulations.
The company delivered robust double-digit growth in both revenue and profitability with expanding margins. However, investors should note the negative operating cash flow of Rs 128.10 Lakh despite healthy profits, indicating working capital build-up. The substantial IPO proceeds remain largely unutilized, which could be deployed for growth initiatives.